aTyr Pharma Inc (LIFE)
4.48
+0.03 +0.67%
NASDAQ
Jul 28, 12:06
USD
View All Key Stats
Key Stats
| Income Statement | |
| Revenue (TTM) | -- |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (TTM) | -2.35 |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Net Income (TTM) | -25.13M |
| Profitability | |
| Gross Profit Margin (Quarterly) | -- |
| Profit Margin (Quarterly) | -- |
| Dividend | |
| Dividend Yield (Forward) | Upgrade |
| Dividend Yield | 0% |
| Price and Valuation | |
| Market Cap | 71.97M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| PS Ratio | 4.698 |
| PE Ratio | -- |
| Price to Book Value | 1.448 |
| Other | |
| Beta (5Y) | Upgrade |
| Debt to Equity Ratio | -- |
| Free Cash Flow (Quarterly) | -5.844M |
| Return on Equity | Upgrade |
View All LIFE News
News
-
WireHeadlineTime (ET)
-
Globe Newswire07/08 08:00
-
Yahoo06/30 10:26
-
Globe Newswire06/23 08:00
-
Globe Newswire06/10 16:30
-
Yahoo06/02 04:58
-
Yahoo05/28 12:20
-
Globe Newswire05/25 08:00
-
Globe Newswire05/19 08:00
-
MT Newswires05/18 08:24
-
Yahoo05/13 17:20
-
Globe Newswire05/13 16:05
-
Yahoo05/13 15:15
-
Globe Newswire05/12 08:00
-
Globe Newswire05/11 08:00
-
MT Newswires05/10 14:40
-
Globe Newswire05/06 08:00
-
Yahoo05/04 15:00
-
Globe Newswire04/20 08:00
-
MT Newswires04/14 08:51
-
Globe Newswire04/14 08:00
View All Events
Events
| Date | Type | Description |
|---|---|---|
| 08/13/2021 | Earnings Results | Q2 2021 Earnings Results |
| 08/13/2021 17:00 EST | Earnings Calls | Q2 2021 Earnings Call |
| 05/13/2021 | Earnings Results | Q1 2021 Earnings Results |
| 05/13/2021 17:00 EST | Earnings Calls | Q1 2021 Earnings Call |
| 04/28/2021 11:30 EST | AGM | 2020 Annual General Meeting |
| 03/23/2021 | Earnings Results | Q4 2020 Earnings Results |
| 03/23/2021 17:00 EST | Earnings Calls | Q4 2020 Earnings Call |
| 11/12/2020 | Earnings Results | Q3 2020 Earnings Results |
| 11/12/2020 17:00 EST | Earnings Calls | Q3 2020 Earnings Call |
| 08/13/2020 17:00 EST | Earnings Calls | Q2 2020 Earnings Call |
Fundamentals
Income Statement View Statement
Ratings & Reports
- Y-Rating Upgrade
- Value Score Upgrade
- Fundamental Score Upgrade
- Valuation (Hist. Mult.) Upgrade
- Y-Rating Report Download
- One Page Report Download
Advertisement
Edit
Profile
- Description: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.
- URL: https://www.atyrpharma.com
- Investor Relations URL: http://atyrpharma.investorroom.com/
- HQ State/Province: California
- Sector: Healthcare
- Industry: Biotechnology
- Equity Style: Small Cap/Value
- Next Earnings Release: Aug. 13, 2021
- Last Earnings Release: May. 13, 2021
- Next Ex-Dividend Date: N/A
- Last Ex-Dividend Date: N/A
Analyst Coverage
| Consensus Recommendations | |
| Buy Recommendations | Upgrade |
| Outperform Recommendations | Upgrade |
| Hold Recommendations | Upgrade |
| Underperform Recommendations | Upgrade |
| Sell Recommendations | Upgrade |
| Consensus Recommendation | Upgrade |
| Consensus Rating | Upgrade |
| Target Price | |
| Price | 4.48 |
| Price Target | Upgrade |
| Price Target Upside (Daily) | Upgrade |
Other Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership Nasdaq
- SEC Filings SEC
- LIFE Tweets Stocktwits
Advertisement
